RET (R912P)
Sign in to save this workspaceRET · Variant type: point · HGVS: p.R912P
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Ponatinib | 100.0% | 0.0% | 78.23 |
| 2 | Pralsetinib | 100.0% | 0.0% | 93.43 |
| 3 | Nintedanib | 99.9% | 0.1% | 90.23 |
| 4 | Tenalisib | 99.9% | 0.1% | 97.98 |
| 5 | Fedratinib | 99.4% | 0.6% | 96.21 |
| 6 | Selpercatinib | 99.4% | 0.6% | 96.72 |
| 7 | Alpelisib | 98.9% | 1.1% | 97.22 |
| 8 | Entrectinib | 98.9% | 1.1% | 93.69 |
| 9 | Tivozanib | 98.8% | 1.2% | 92.42 |
| 10 | Alectinib | 97.8% | 2.2% | 95.49 |
| 11 | Gilteritinib | 97.5% | 2.5% | 88.97 |
| 12 | Lenvatinib | 96.6% | 3.4% | 97.74 |
| 13 | Vandetanib | 96.2% | 3.8% | 95.74 |
| 14 | Regorafenib | 95.8% | 4.2% | 95.99 |
| 15 | Sunitinib | 95.4% | 4.6% | 91.73 |
| 16 | Sorafenib | 94.9% | 5.1% | 96.72 |
| 17 | Brigatinib | 94.7% | 5.3% | 82.96 |
| 18 | Futibatinib | 93.6% | 6.4% | 98.48 |
| 19 | Repotrectinib | 93.6% | 6.4% | 84.21 |
| 20 | Erdafitinib | 92.8% | 7.2% | 95.71 |
| 21 | Cabozantinib | 92.0% | 8.0% | 92.73 |
| 22 | Avapritinib | 90.0% | 10.0% | 97.73 |
| 23 | Axitinib | 89.8% | 10.2% | 93.23 |
| 24 | Fostamatinib | 88.6% | 11.4% | 96.74 |
| 25 | Ripretinib | 86.7% | 13.3% | 92.95 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Ponatinib | 100.0% | 100.0% | +0.0% |
| Pralsetinib | 100.0% | 100.0% | +0.0% |
| Nintedanib | 99.9% | 100.0% | -0.1% |
| Tenalisib | 99.9% | 98.5% | +1.4% |
| Fedratinib | 99.4% | 99.9% | -0.4% |
| Selpercatinib | 99.4% | 100.0% | -0.6% |
| Alpelisib | 98.9% | 99.6% | -0.7% |
| Entrectinib | 98.9% | 99.6% | -0.7% |
| Tivozanib | 98.8% | 99.7% | -1.0% |
| Alectinib | 97.8% | 97.8% | -0.0% |
| Gilteritinib | 97.5% | 100.0% | -2.5% |
| Lenvatinib | 96.6% | 98.8% | -2.3% |
| Vandetanib | 96.2% | 98.6% | -2.4% |
| Regorafenib | 95.8% | 98.7% | -2.9% |
| Sunitinib | 95.4% | 97.2% | -1.8% |
| Sorafenib | 94.9% | 94.0% | +1.0% |
| Brigatinib | 94.7% | 94.9% | -0.2% |
| Futibatinib | 93.6% | 97.7% | -4.1% |
| Repotrectinib | 93.6% | — | — |
| Erdafitinib | 92.8% | 94.7% | -1.9% |
| Cabozantinib | 92.0% | 97.5% | -5.5% |
| Avapritinib | 90.0% | — | — |
| Axitinib | 89.8% | — | — |
| Fostamatinib | 88.6% | — | — |
| Ripretinib | 86.7% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| carcinoma_thyroid | Thyroid | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 14.6ms